Harrow, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number
Harrow, Inc. (HROW) reported Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number of 130.46 thousand shares for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-23.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber · last filed 2016-03-23
- Harrow, Inc. share-based compensation arrangement by share-based payment award, accelerated vesting, number for the quarter ending 2015-12-31 was 109.28K shares.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, accelerated vesting, number for the quarter ending 2015-09-30 was 11.25K shares.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, accelerated vesting, number for fiscal 2015 was 130.46K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number 12 month |
|---|---|---|---|---|
| 2015-12-31 | 109.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | 120.52K shares derived: sum of 2 quarters · filed 2016-03-23 | 130.46K shares 10-K · filed 2016-03-23 | |
| 2015-09-30 | 11.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | 21.18K shares 10-Q · filed 2015-11-12 | ||
| 2015-06-30 | 9.94K shares 10-Q · filed 2015-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |